株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

腫瘍溶解性ウイルス:パイプライン・ステークホルダー・取引・産業動向・機会の分析

The Oncolytic Virus Landscape 2017: An Analysis of Pipeline, Stakeholders, Deals, Industry Trends & Opportunities

発行 La Merie Publishing 商品コード 425869
出版日 ページ情報 英文 225 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.25円で換算しております。
Back to Top
腫瘍溶解性ウイルス:パイプライン・ステークホルダー・取引・産業動向・機会の分析 The Oncolytic Virus Landscape 2017: An Analysis of Pipeline, Stakeholders, Deals, Industry Trends & Opportunities
出版日: 2017年01月26日 ページ情報: 英文 225 Pages
概要

当レポートでは、腫瘍溶解性ウイルスについて調査分析し、主要企業、主要技術、プロジェクト、事業取引、民間・公的融資に関する最新動向について、体系的な情報を提供しています。

第1章 エグゼクティブサマリー

第2章 イントロダクション・概要

第3章 腫瘍溶解性ウイルスの選択、設計、構築

  • 単純ヘルペスウイルス (HSV) 系
  • アデノウイルス系
  • ワクシニアウイルス系
  • 水疱性口内炎ウイルス (VSV) 系
  • ニューカッスル病ウイルス (NDV) 系
  • その他の腫瘍溶解性ウイルス

第4章 腫瘍溶解性ウイルスのプロファイル

  • 単純ヘルペスウイルス (HSV) 系
  • アデノウイルス系
  • ワクシニアウイルス系
  • 水疱性口内炎ウイルス (VSV) 系
  • ニューカッスル病ウイルス (NDV) 系
  • その他の腫瘍溶解性ウイルス
  • 幹細胞デリバリー腫瘍溶解性ウイルス

第5章 腫瘍溶解性ウイルスのパイプライン分析

  • 腫瘍溶解性ウイルスのパイプラインの概要
  • 承認・上市済みの腫瘍溶解性ウイルス
  • 後期開発段階の腫瘍溶解性ウイルス
  • 免疫チェックポイント阻害薬・その他の抗がん剤と腫瘍溶解性ウイルスの組み合わせ
  • 腫瘍溶解性ウイルス

第6章 企業プロファイル

  • 大手製薬・バイオテクノロジー企業
    • Amgen
    • Astellas Pharma
    • AstraZeneca
    • Boehringer Ingelheim
    • Bristol-Myers Squibb
    • Celgene
    • 第一三共
    • Green Cross
    • Jiangsu Hengrui
    • Lee Pharma
    • Medigen Biotechnology
    • Merck
    • 大塚製薬
    • Pfizer
    • Roche
  • 第1世代の腫瘍溶解性ウイルス企業
    • Cold Genesys
    • Genelux
    • Latima
    • Multivir/VirRx
    • Neotropix
    • Oncolytics Biotech
    • Shanghai Sunway Biotech
    • SillaJen
    • タカラバイオ
    • Theravir
    • Virttu Biologics & TNK Therapeutics
    • Wellstat Biologics
  • 第2世代の腫瘍溶解性ウイルス企業
    • DNAtrix
    • Oncolys BioPharma
    • ORCA Therapeutics
    • Oryx
    • Targovax
    • VCN Biosciences
    • Viralytics
  • 第3世代の腫瘍溶解性ウイルス企業
    • Benevir BioPharm
    • Lokon Pharma
    • PsiOxus Therapeutics
    • Transgene
  • 第4世代の腫瘍溶解性ウイルス企業
    • Duke University Start-Up Company
    • IGNITE Immunotherapy
    • Oncorus
    • Replimmune
    • TILT Biotherapeutics
    • Turnstone Biologics
    • Unleash Immuno Oncolytics
    • ViraTherapeutics
    • Vyriad
    • Western Oncolytics

第7章 ステークホルダー分析

第8章 融資・提携

第9章 動向・機会

第10章 参考資料

目次
Product Code: LMFR0022

The field of oncolytic viruses was quite dormant in the first decade of the 2000s, characterized by slow clinical progress due to hypercautiousness and low, albeit steady, investments. The takeover of BioVex by Amgen in late 2011, worth up to US$ 1 bln, has woken up the field and became a game changer together with the 2015 approval of the first oncolytic virus Imlygic developed by BioVex in regulated markets. In addition, it was increasingly recognized that oncolytic viruses not only were able to directly lyse cancer cells, but they also "freed" tumor specific neoantigens, indirectly acting as a cancer vaccine.

However, the efficacy of oncolytic viruses still was modest, but can be improved when combined with immune checkpoint inhibitors. This lead to an increased partnering interest of the major immuno-oncology (I-O) players, but also of investors who view oncolytic viruses as a must be for I-O combination regimens. As a consequence, total venture equity and private investments into oncolytic virus companies in 2016 was nearly 17-fold higher than in the year 2010.

Optimization of oncolytic viruses is ongoing and new constructs intend to solve some of the open problems regarding the way of administration (intratumoral vs systemic), higher cancer cell specific replication capacity, and longer persistence in vivo. Based on experience with several virus families over the last decades, a few virus families cristallized as well suitable backbones to carry more and more transgenes to express proteins or even single chain antibodies. This would position oncolytic viruses as independent therapeutics and could compete with immuno-oncology compounds and cancer vaccines.

This report " The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities " as of January 2017 brings you up-to-date regarding key players, key technologies, Oncolytic Virus projects, business deals and private and public financing rounds. The report analyzes the Oncolytic Virus pipeline and stakeholders in the field, especially among Big Pharma/Biotech and technology companies. The report highlights the value of oncolytic viruses in terms of partnering terms and conditions, venture and private financing and (initial) public offerings.

This report has been built in a bottom-up way by desktop search to identify and describe company, product, technology and business/financing profiles which then were evaluated and analyzed with a final outlook describing perspectives with challenges and opportunities.

What will you find in the report?

  • Selection of oncolytic virus strains
  • Design & construction of engineered oncolytic viruses
  • Herpes simplex virus (HSV) family
  • Adenovirus-based oncolytic viruses
  • Oncolytic Vaccinia Viruses, Vesicular Stomatitis Viruses, Newcastle Disease Viruses & Others
  • Profiles of 45 oncolytic viruses in development and on the market;
  • Analysis of the pipeline of oncolytic viruses
  • Comparison of clinical development paths
  • Combination trials of oncolytic viruses with immune checkpoint inhibitors
  • Combination with other anticancer therapeutics
  • Armed oncolytic viruses
  • Tumor indication of oncolytic viruses under study
  • Way of administration of oncolytic viruses in clinical studies
  • Profiles of 45 companies active in the field of oncolytic viruses
  • Pharma & Biotech vs four generations of oncolytic virus companies
  • Stakeholder analysis within each peer group
  • Sources of oncolytic virus technologies
  • Sources of non-dilutive financing including partnering deals
  • Analysis of venture and private equity financing rounds
  • Listing on stock exchange for access to capital
  • Mergers and acquisition in the field
  • Trends in the further research and development of oncolytic viruses

Who will benefit from the report?

  • Venture capital, private equity and investment managers;
  • Financial analysts;
  • CFO;
  • Business development and licensing (BDL) specialists;
  • Marketing managers;
  • CEO, COO and managing directors;
  • Corporate strategy, product and portfolio analysts and managers;
  • Chief Technology Officer;
  • Cell technology and manufacturing specialists;
  • Clinical and preclinical development specialists.

Table of Contents

1 Executive Summary

2 Introduction & Overview

3 Selection, Design & Construction of Oncolytic Viruses

  • 3.1 Herpes Simplex Virus (HSV) - based Oncolytic Viruses
  • 3.2 Adenoviruses - based Oncolytic Viruses
  • 3.3 Vaccinia Virus - Based Oncolytic Viruses
  • 3.4 Vesicular Stomatitis Virus - based Oncolytic Viruses
  • 3.5 Newcastle Disease Virus - based Oncolytic Viruses
  • 3.6 Various Oncolytic Viruses

4 Profiles of Oncolytic Viruses

  • 4.1 HSV-based Oncolytic Viruses
    • 4.1.1 Imlygic; talimogene laherparepvec; T-Vec; OncoVEX(GM-CSF)
    • 4.1.2 G47Δ
    • 4.1.3 HF10; TB-1401
    • 4.1.4 HSV1716; seprehvir
    • 4.1.5 HSV-Rb-p450
    • 4.1.6 BV-2711
    • 4.1.7 ONCR-001
  • 4.2 Adenovirus-based Oncolytic Viruses
    • 4.2.1 Oncorine
    • 4.2.2 CG0070
    • 4.2.3 DNX-2401
    • 4.2.4 OBP-301; telomelysin
    • 4.2.5 ONCOS-102
    • 4.2.6 Enadenotucirev; ColoAd1
    • 4.2.7 Adenoviral VirRx 007; INGN 007; VRX-007
    • 4.2.8 VCN-01
    • 4.2.9 LOAd703
    • 4.2.10 H103
    • 4.2.11 NG-348
    • 4.2.12 ORCA-010
    • 4.2.13 TILT-123
    • 4.2.14 UIO-112
    • 4.2.15 TILT-324
    • 4.2.16 DNX-2440; Delta-24-RGDOX
    • 4.2.17 DNX-2450
    • 4.2.18 OBP-702
  • 4.3 Vaccinia Virus-based Oncolytic Viruses
    • 4.3.1 Pexastimogene devacirepvec; Pexa-Vec; JX-594; TG6006
    • 4.3.2 GL-ONC1
    • 4.3.3 JX-929; vvDD
    • 4.3.4 TG6002
    • 4.3.5 WO-12
  • 4.4 Vesicular Stomatitis Virus-based Oncolytic Viruses
    • 4.4.1 MG1 Maraba/MAGE-A3 (MG1MA3)
    • 4.4.2 VSV-IFNbeta
    • 4.4.3 VSV-IFNbeta-NIS
    • 4.4.4 VSV-GP
  • 4.5 Newcastle Disease Virus-based Oncolytic Viruses
    • 4.5.1 NDV-HUJ
    • 4.5.2 PV701
    • 4.5.3 recNDVGM-CSF
  • 4.6 Various Oncolytic Viruses
    • 4.6.1 Rigvir
    • 4.6.2 Reolysin; pelareorep
    • 4.6.3 CAVATAK; CVA21
    • 4.6.4 MV-NIS
    • 4.6.5 NTX-010; SVV-001
    • 4.6.6 H-1PV
    • 4.6.7 PVS-RIPO
    • 4.6.8 MYX-135
  • 4.7 Stem Cell-delivered Oncolytic Viruses
    • 4.7.1 TBX.OncV (CRad-Survivan-pk7)
    • 4.7.2 MSC-ICOVIR-5

5 Analysis of Oncolytic Virus Pipeline

  • 5.1 Overview of the Pipeline of Oncolytic Viruses
  • 5.2 Approved and Marketed Oncolytic Viruses
  • 5.3 Late Stage Development of Oncolytic Viruses
  • 5.4 Combination of Oncolytic Viruses with Immune Checkpoint Inhibitors and Other Anti-Tumor Agents
  • 5.5 Armed Oncolytic Viruses

6 Company Profiles

  • 6.1 Pharma & Biotech
    • 6.1.1 Amgen
    • 6.1.2 Astellas Pharma
    • 6.1.3 AstraZeneca
    • 6.1.4 Boehringer Ingelheim
    • 6.1.5 Bristol-Myers Squibb
    • 6.1.6 Celgene
    • 6.1.7 Daiichi Sankyo
    • 6.1.8 Green Cross
    • 6.1.9 Jiangsu Hengrui
    • 6.1.10 Lee Pharma
    • 6.1.11 Medigen Biotechnology
    • 6.1.12 Merck
    • 6.1.13 Otsuka Pharmaceutical Co
    • 6.1.14 Pfizer
    • 6.1.15 Roche
  • 6.2 First Generation Oncolytic Virus Companies
    • 6.2.1 Cold Genesys
    • 6.2.2 Genelux
    • 6.2.3 Latima
    • 6.2.4 Multivir / VirRx
    • 6.2.5 Neotropix
    • 6.2.6 Oncolytics Biotech
    • 6.2.7 Shanghai Sunway Biotech
    • 6.2.8 SillaJen
    • 6.2.9 Takara Bio
    • 6.2.10 Theravir
    • 6.2.11 Virttu Biologics & TNK Therapeutics
    • 6.2.12 Wellstat Biologics
  • 6.3 Second Generation Oncolytic Virus Companies
    • 6.3.1 DNAtrix
    • 6.3.2 Oncolys BioPharma
    • 6.3.3 ORCA Therapeutics
    • 6.3.4 Oryx
    • 6.3.5 Targovax
    • 6.3.6 VCN Biosciences
    • 6.3.7 Viralytics
  • 6.4 Third Generation Oncolytic Virus Companies
    • 6.4.1 Benevir BioPharm
    • 6.4.2 Lokon Pharma
    • 6.4.3 PsiOxus Therapeutics
    • 6.4.4 Transgene
  • 6.5 Fourth Generation Oncolytic Virus Companies
    • 6.5.1 Duke University Start-Up Company
    • 6.5.2 IGNITE Immunotherapy
    • 6.5.3 Oncorus
    • 6.5.4 Replimmune
    • 6.5.5 TILT Biotherapeutics
    • 6.5.6 Turnstone Biologics
    • 6.5.7 Unleash Immuno Oncolytics
    • 6.5.8 ViraTherapeutics
    • 6.5.9 Vyriad
    • 6.5.10 Western Oncolytics

7 Stakeholder Analysis

  • 7.1 Pharma & Biotech
  • 7.2 First Generation Oncolytic Virus Companies
  • 7.3 Second Generation Oncolytic Virus Companies
  • 7.4 Third Generation Oncolytic Virus Companies
  • 7.5 Fourth Generation Oncolytic Virus Companies

8 Financing & Partnering

  • 8.1 Grants, Credits & Donations
  • 8.2 Venture Capital, Private Equity & Private Placements
  • 8.3 Partnering Deals
  • 8.4 Listing on the Stock Market
  • 8.5 Mergers & Acquisitions

9 Trends & Opportunities

10 References

Tables in the Text:

  • Table 1: Selection, Design & Construction of HSV - based Oncolytic Viruses
  • Table 2: Selection, Design & Construction of Adenovirus - based Oncolytic Viruses
  • Table 3: Selection, Design & Construction of Vaccinia Virus - based Oncolytic Viruses
  • Table 4: Selection, Design & Construction of Vesicular Stomatitis Virus - based Oncolytic Viruses
  • Table 5: Selection, Design & Construction of Newcastle Disease Virus - based Oncolytic Viruses
  • Table 6: Selection, Design & Construction of Various Virus - based Oncolytic Viruses
  • Table 7: Current Company-Sponsored Clinical Trials of T-Vec
  • Table 8: Clinical Trials of ColoAd1
  • Table 9: Clinical Trials with JX-594
  • Table 10: Clinical Trials with GL-ONC1
  • Table 11: Clinical Trials of CAVATAK (CVA21)
  • Table 12: Clinical Trials with MV-NIS
  • Table 13: Overview of Oncolytic Viruses by Development Phase & Virus Family
  • Table 14: Profile of Approved and Marketed Oncolytic Viruses
  • Table 15: Pivotal Study Design of Oncolytic Viruses in Late Stage Development Based on Previous Clinical Results
  • Table 16: Approved Indications of Immune Checkpoint Inhibitors
  • Table 17: Active Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI)
  • Table 18: Planned Clinical Studies of Oncolytic Viruses in Combination with Immune Checkpoint Inhibitors (ICI)
  • Table 19: Active or Planned Clinical Studies of Oncolytic Viruses in Combination with Other Anti-Cancer Therapeutics
  • Table 20: Pattern of Transgenes in Oncolytic Viruses in Relation to Development Phase
  • Tables 21a and 21b: Indications and Frquency and Way of Administration of Oncolytic Viruses in Active and/or Positive Completed Clinical Studies
  • Table 22: Small and Medium Pharma & Biotech as Partner for Regional Co-Development of Oncolytic Viruses
  • Table 23: Immuno-Oncology Portfolio of Major Pharma & Biotech with Interest in Oncolytic Viruses
  • Table 24: Interests of Major Pharma & Biotech in Oncolytic Viruses
  • Table 25: First Generation Oncology Virus Companies and their Sources of Technology
  • Table 26: Second Generation Oncology Virus Companies and their Sources of Technology
  • Table 27: Third Generation Oncology Virus Companies and their Sources of Technology
  • Table 28: Fourth Generation Oncology Virus Companies and their Sources of Technology
  • Table 29: Grants, Credits & Donations
  • Table 30: Financing by Venture Capital, Private Equity and Other Private Placements
  • Table 31: Collaboration & Licensing Agreements
  • Table 32: Companies Listed on Stock Exchange & Offerings
  • Table 33: Mergers & Acquisitions

Companies mentioned in the report

  • Amgen
  • Astellas Pharma
  • AstraZeneca (MedImmune)
  • Bayer
  • Benevir Biopharm
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celgene
  • Cold Genesys
  • Daiichi Sankyo
  • DNAtrix
  • Duke University start-up Company
  • GeneLux
  • Green Cross
  • Grifols
  • GSK (GlaxoSmithKline)
  • IGNITE Immunotherapy
  • Jiangsu Hengrui
  • Latima
  • Lee's Pharma
  • Lokon Pharma
  • Medigen Biotechnology
  • Merck
  • Multivir
  • Neotropix
  • Oncolys BioPharma
  • Oncolytics Biotech
  • Oncorus
  • Orca Therapeutics
  • Oryx
  • Otsuka Pharmaceutical Co
  • Pfizer
  • Profectus Biosciences
  • PsiOxus
  • Replimune
  • Roche
  • Shanghai Sunway Biotech
  • SillaJen
  • Sotio
  • StemImmune
  • StingInn
  • Takara Bio
  • Targovax
  • TheraBiologics
  • Theravir
  • TILT Biotherapeutics
  • Transgene
  • Turnstone Biologics
  • Unleash Immuno Oncolytics
  • VCN Biosciences
  • Viralytics
  • ViraTherapeutics
  • Virttu Biologics (TNK Therapeutics)
  • Vyriad
  • Wellstat Biologics
  • Western Oncolytics
Back to Top